Sho Iketani

7.0k total citations · 5 hit papers
25 papers, 2.3k citations indexed

About

Sho Iketani is a scholar working on Infectious Diseases, Molecular Biology and Immunology. According to data from OpenAlex, Sho Iketani has authored 25 papers receiving a total of 2.3k indexed citations (citations by other indexed papers that have themselves been cited), including 19 papers in Infectious Diseases, 10 papers in Molecular Biology and 5 papers in Immunology. Recurrent topics in Sho Iketani's work include SARS-CoV-2 and COVID-19 Research (15 papers), COVID-19 Clinical Research Studies (6 papers) and Viral gastroenteritis research and epidemiology (4 papers). Sho Iketani is often cited by papers focused on SARS-CoV-2 and COVID-19 Research (15 papers), COVID-19 Clinical Research Studies (6 papers) and Viral gastroenteritis research and epidemiology (4 papers). Sho Iketani collaborates with scholars based in United States, Hong Kong and Japan. Sho Iketani's co-authors include David D. Ho, Yicheng Guo, Zizhang Sheng, Lihong Liu, Jian Yu, Maple Wang, Yaoxing Huang, Qian Wang, Zhiteng Li and Harris H. Wang and has published in prestigious journals such as Nature, Cell and Nature Communications.

In The Last Decade

Sho Iketani

25 papers receiving 2.3k citations

Hit Papers

5 papers align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Alarming antibody evasion properties of rising SARS-CoV-2 BQ and XBB subvariants

2022 495 citations Qian Wang, Sho Iketani et al. Cell profile →
Antibody evasion properties of SARS-CoV-2 Omicron sublineages

2022 478 citations Sho Iketani, Lihong Liu et al. Nature profile →
Antibody evasion by SARS-CoV-2 Omicron subvariants BA.2.12.1, BA.4 and BA.5

2022 433 citations Qian Wang, Yicheng Guo et al. Nature profile →
Multiple pathways for SARS-CoV-2 resistance to nirmatrelvir

2022 260 citations Sho Iketani, Hiroshi Mohri et al. Nature profile →
Antigenicity and receptor affinity of SARS-CoV-2 BA.2.86 spike

2023 100 citations Qian Wang, Yicheng Guo et al. Nature profile →

Peers

Countries citing papers authored by Sho Iketani

Since Specialization

Citations

This map shows the geographic impact of Sho Iketani's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Sho Iketani with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Sho Iketani more than expected).

Fields of papers citing papers by Sho Iketani

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Sho Iketani. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Sho Iketani. The network helps show where Sho Iketani may publish in the future.

Co-authorship network of co-authors of Sho Iketani

This figure shows the co-authorship network connecting the top 25 collaborators of Sho Iketani. A scholar is included among the top collaborators of Sho Iketani based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Sho Iketani. Sho Iketani is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Development of small molecule non-covalent coronavirus 3CL protease inhibitors from DNA-encoded chemical library screening 2025 ·Nature Communications ·Hengrui Liu, Arie Zask, F. Forouhar, Sho Iketani, (unknown), (unknown), (unknown), Kwan Sam Choi, (unknown), Seo Jung Hong, David H. Lovett, Tian Bai, Alejandro Chavez, David D. Ho, Brent R. Stockwell	1
2	SARS-CoV-2 resistance to monoclonal antibodies and small-molecule drugs 2024 ·Cell chemical biology ·Sho Iketani, David D. Ho	14
3	Evolving antibody evasion and receptor affinity of the Omicron BA.2.75 sublineage of SARS-CoV-2 2023 ·iScience ·Qian Wang, Zhiteng Li, Yicheng Guo, Ian A. Mellis, Sho Iketani, Michael Liu, Jian Yu, Riccardo Valdez, Adam S. Lauring, Zizhang Sheng, Aubree Gordon, Lihong Liu, David D. Ho	13
4	Antigenicity and receptor affinity of SARS-CoV-2 BA.2.86 spike breakdown → 2023 ·Nature ·Qian Wang, Yicheng Guo, Liyuan Liu, (unknown), Zhiteng Li, Manoj S. Nair, Jerren Ho, (unknown), Sho Iketani, Jian Yu, Yiming Huang, Yiming Qu, Riccardo Valdez, Adam S. Lauring, Yaoxing Huang, Aubree Gordon, Harris H. Wang, Lihong Liu, David D. Ho	100
5	Antibodies targeting a quaternary site on SARS-CoV-2 spike glycoprotein prevent viral receptor engagement by conformational locking 2023 ·Immunity ·Lihong Liu, Ryan G. Casner, Yicheng Guo, Qian Wang, Sho Iketani, Jasper Fuk‐Woo Chan, Jian Yu, Bernadeta Dadonaite, Manoj S. Nair, Hiroshi Mohri, Eswar R. Reddem, Shuofeng Yuan, Vincent Kwok‐Man Poon, Chris Chung‐Sing Chan, Kwok‐Yung Yuen, Zizhang Sheng, Yaoxing Huang, Jesse D. Bloom, Lawrence Shapiro, David D. Ho	12
6	Antibody evasion properties of SARS-CoV-2 Omicron sublineages breakdown → 2022 ·Nature ·Sho Iketani, Lihong Liu, Yicheng Guo, Liyuan Liu, Jasper Fuk‐Woo Chan, Yiming Huang, Maple Wang, Yang Luo, Jian Yu, Hin Chu, (unknown), (unknown), Michael T. Yin, Magdalena E. Sobieszczyk, Yaoxing Huang, Kwok‐Yung Yuen, Harris H. Wang, Zizhang Sheng, David D. Ho	478
7	Antibody evasion by SARS-CoV-2 Omicron subvariants BA.2.12.1, BA.4 and BA.5 breakdown → 2022 ·Nature ·Qian Wang, Yicheng Guo, Sho Iketani, Manoj S. Nair, Zhiteng Li, Hiroshi Mohri, Maple Wang, Jian Yu, Anthony Bowen, Jennifer Y. Chang, Jayesh Shah, Nadia Nguyen, Zhiwei Chen, Kathrine Meyers, Michael T. Yin, Magdalena E. Sobieszczyk, Zizhang Sheng, Yaoxing Huang, Lihong Liu, David D. Ho	433
8	Multiple pathways for SARS-CoV-2 resistance to nirmatrelvir breakdown → 2022 ·Nature ·Sho Iketani, Hiroshi Mohri, Bruce Culbertson, Seo Jung Hong, Yinkai Duan, Maria I. Luck, Medini K. Annavajhala, Yicheng Guo, Zizhang Sheng, Anne‐Catrin Uhlemann, Stephen P. Goff, Yosef Sabo, Haitao Yang, Alejandro Chavez, David D. Ho	260
9	Alarming antibody evasion properties of rising SARS-CoV-2 BQ and XBB subvariants breakdown → 2022 ·Cell ·Qian Wang, Sho Iketani, Zhiteng Li, Liyuan Liu, Yicheng Guo, Yiming Huang, Anthony Bowen, Michael Liu, Maple Wang, Jian Yu, Riccardo Valdez, Adam S. Lauring, Zizhang Sheng, Harris H. Wang, Aubree Gordon, Lihong Liu, David D. Ho	495
10	Functional map of SARS-CoV-2 3CL protease reveals tolerant and immutable sites 2022 ·Cell Host & Microbe ·Sho Iketani, Seo Jung Hong, (unknown), (unknown), Bruce Culbertson, Fereshteh Fallah Atanaki, Arjun K. Aditham, Alexander Kratz, Maria I. Luck, (unknown), Stephen P. Goff, Hesam Montazeri, Yosef Sabo, David D. Ho, Alejandro Chavez	32
11	Antigenic characterization of the SARS-CoV-2 Omicron subvariant BA.2.75 2022 ·Cell Host & Microbe ·Qian Wang, Sho Iketani, Zhiteng Li, Yicheng Guo, (unknown), Michael Liu, Jian Yu, Zizhang Sheng, Yaoxing Huang, Lihong Liu, David D. Ho	58
12	Functional properties of the spike glycoprotein of the emerging SARS-CoV-2 variant B.1.1.529 2022 ·Cell Reports ·Qian Wang, Saumya Anang, Sho Iketani, Yicheng Guo, Lihong Liu, Phinikoula S. Katsamba, Lawrence Shapiro, David D. Ho, Joseph Sodroski	22
13	Author Correction: Lead compounds for the development of SARS-CoV-2 3CL protease inhibitors 2021 ·Nature Communications ·Sho Iketani, F. Forouhar, Hengrui Liu, Seo Jung Hong, Fang-Yu Lin, Manoj S. Nair, Arie Zask, Yaoxing Huang, Xing Li, Brent R. Stockwell, Alejandro Chavez, David D. Ho	8
14	Lead compounds for the development of SARS-CoV-2 3CL protease inhibitors 2021 ·Nature Communications ·Sho Iketani, F. Forouhar, Hengrui Liu, Seo Jung Hong, Fang-Yu Lin, Manoj S. Nair, Arie Zask, Yaoxing Huang, Xing Li, Brent R. Stockwell, Alejandro Chavez, David D. Ho	79
15	CRISPR-based gene knockout screens reveal deubiquitinases involved in HIV-1 latency in two Jurkat cell models 2020 ·Scientific Reports ·Anurag S. Rathore, Sho Iketani, Pengfei Wang, (unknown), (unknown), David D. Ho	34
16	Targeted Co-delivery of Tumor Antigen and α-Galactosylceramide to CD141+ Dendritic Cells Induces a Potent Tumor Antigen-Specific Human CD8+ T Cell Response in Human Immune System Mice 2020 ·Frontiers in Immunology ·Jing Huang, Jing Zhou, (unknown), Toshiyuki Seki, Sho Iketani, Daphnée Soulard, Patrick Paczkowski, Yukiko Tsuji, Sean Mackay, Luis J. Cruz, François Trottein, Moriya Tsuji	19
17	Functional Human CD141+ Dendritic Cells in Human Immune System Mice 2019 ·The Journal of Infectious Diseases ·Jordana Grazziela Alves Coelho-dos-Reis, (unknown), Jing Huang, Felipe V. Pereira, Sho Iketani, Moriya Tsuji	5
18	Influenza virus uses transportin 1 for vRNP debundling during cell entry 2019 ·Nature Microbiology ·Y. Miyake, J.J. Keusch, Laure Decamps, (unknown), Sho Iketani, H. Gut, Ulrike Kutay, Ari Helenius, Yohei Yamauchi	53
19	Comparing the functions of equine and canine influenza H3N8 virus PA-X proteins: Suppression of reporter gene expression and modulation of global host gene expression 2016 ·Virology ·(unknown), Miao Sun, Sho Iketani, Edward C. Holmes, Colin R. Parrish	15
20	Characterization of the Molecular Interaction between Tropoelastin and DANCE/Fibulin-5 2008 ·The Journal of Biochemistry ·Hiroshi Wachi, Risa Nonaka, Fumiaki Sato, (unknown), M. Ishida, Sho Iketani, Iori Maeda, Koji Okamoto, Zsolt Urbán, Satomi Onoue, Yasuji Seyama	29

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact